Phoenix Financial Ltd. Acquires 12,828 Shares of Novo Nordisk A/S $NVO

Phoenix Financial Ltd. grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 11.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 122,154 shares of the company’s stock after buying an additional 12,828 shares during the period. Phoenix Financial Ltd.’s holdings in Novo Nordisk A/S were worth $6,213,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Capital International Investors boosted its holdings in shares of Novo Nordisk A/S by 52.4% during the 3rd quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock worth $982,969,000 after buying an additional 6,092,192 shares in the last quarter. Franklin Resources Inc. boosted its holdings in shares of Novo Nordisk A/S by 4,190.8% during the 3rd quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock worth $776,016,000 after buying an additional 13,658,867 shares in the last quarter. Folketrygdfondet lifted its holdings in shares of Novo Nordisk A/S by 1.2% in the 3rd quarter. Folketrygdfondet now owns 10,211,913 shares of the company’s stock worth $566,659,000 after purchasing an additional 117,370 shares in the last quarter. State Street Corp lifted its holdings in shares of Novo Nordisk A/S by 1.0% in the 3rd quarter. State Street Corp now owns 6,106,836 shares of the company’s stock worth $340,125,000 after purchasing an additional 59,153 shares in the last quarter. Finally, Boston Partners bought a new position in shares of Novo Nordisk A/S in the 3rd quarter worth $310,199,000. 11.54% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, February 23rd. Sanford C. Bernstein assumed coverage on Novo Nordisk A/S in a report on Wednesday, March 18th. They issued an “outperform” rating and a $175.00 target price on the stock. BMO Capital Markets reiterated a “market perform” rating on shares of Novo Nordisk A/S in a report on Thursday, February 5th. Nordea Equity Research cut Novo Nordisk A/S to a “hold” rating in a report on Tuesday, February 24th. Finally, Morgan Stanley upgraded Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 target price on the stock in a report on Tuesday, March 3rd. Four research analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $65.56.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: New clinical data for oral Wegovy and higher-dose Wegovy showed strong weight-loss results, improved mobility, and broader benefits, reinforcing Novo Nordisk’s obesity-growth story and helping offset worries about slowing momentum. Novo Nordisk (NVO) Announces Positive Early Response Data from Oral Wegovy (25 mg) Trial
• Positive Sentiment: The company’s latest Q1 results beat expectations and it raised its 2026 outlook, which supports the case that newer product launches are still driving sales growth. Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly’s Growing Pressure?
• Positive Sentiment: Investor-friendly commentary and bullish takes continue to highlight Novo Nordisk as undervalued relative to its long-term growth potential, especially if new indications expand its blockbuster franchise. Best Healthcare Stocks to Buy in 2026
• Neutral Sentiment: Several market commentaries and analyst forecast pages were published on NVO, but they appear to be mostly rating/price-target updates rather than new company-specific catalysts. Novo Nordisk A/S (NVO) stock forecast and price target
• Neutral Sentiment: Novo Nordisk also disclosed gifted share transactions linked to CFO associates, which is worth noting but does not by itself appear to change the company’s fundamentals. Novo Nordisk Discloses Gifted Share Transactions Linked to CFO Associates
• Negative Sentiment: Bearish commentary argues Novo Nordisk’s valuation may still be a value trap, and competition from Eli Lilly’s expanding GLP-1 pipeline remains a real threat to obesity-market share. Novo Nordisk: Why I Won’t Upgrade

Novo Nordisk A/S Trading Down 2.7%

Shares of Novo Nordisk A/S stock opened at $45.82 on Friday. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $81.44. The firm has a market cap of $204.60 billion, a PE ratio of 10.76, a P/E/G ratio of 4.19 and a beta of 0.77. The stock has a fifty day moving average price of $39.61 and a 200-day moving average price of $46.71. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The firm had revenue of $10.85 billion during the quarter. Equities research analysts anticipate that Novo Nordisk A/S will post 3.47 EPS for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.